JPMorgan Chase & Co. Has $4.84 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

JPMorgan Chase & Co. increased its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 443.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 168,866 shares of the company's stock after purchasing an additional 137,795 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.22% of CG Oncology worth $4,843,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in CG Oncology by 15.3% during the fourth quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock valued at $168,096,000 after purchasing an additional 779,730 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of CG Oncology in the fourth quarter valued at approximately $100,000. iA Global Asset Management Inc. bought a new stake in shares of CG Oncology in the fourth quarter valued at approximately $1,316,000. Teacher Retirement System of Texas bought a new stake in shares of CG Oncology in the fourth quarter valued at approximately $342,000. Finally, Intech Investment Management LLC bought a new stake in shares of CG Oncology in the fourth quarter valued at approximately $481,000. Institutional investors and hedge funds own 26.56% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. TD Cowen assumed coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a research report on Monday, March 31st. Scotiabank assumed coverage on CG Oncology in a research report on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price for the company. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $55.00 target price on shares of CG Oncology in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $59.33.

CG Oncology Trading Up 1.2 %

Shares of CGON stock traded up $0.25 on Thursday, reaching $20.98. The company had a trading volume of 88,159 shares, compared to its average volume of 727,016. The company has a 50-day moving average of $23.85 and a 200-day moving average of $29.48. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $46.99. The stock has a market cap of $1.60 billion, a PE ratio of -14.71 and a beta of 1.24.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.11 million. Sell-side analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.